UPPSALA, Sweden — Biotage AB (STO:BIOT) today announces that the company invests 15 MDKK into the biomolecule area through the subscription of new shares in the Danish company Chreto Aps.

Biomolecules is one of the fastest growing areas in drug development today and includes monoclonal antibodies-based drugs being used for the treatment of various diseases like for example rheumatoid arthritis, and cancer. The routes to developing biomolecules do not follow the same synthetic pathways as small molecule drug development, and today the purification of biomolecules is often complicated and expensive.

”This investment makes an exciting part of our long-term strategic efforts. Investing in biomolecules is in line with the market trend of an increasing number of drugs based on large molecules such as for example peptides and proteins. We already have products for drug development based on peptides and are now taking one step further towards strengthening Biotage’s future offering in the biomolecule